koto_feja Evotec SE ( NASDAQ: EVO ) has earned a $50M milestone payment from Bristol Myers Squibb ( NYSE: BMY ) under a partnership that began in 2018 to develop molecular glue degraders as treatments, starting in oncology. With the program-based payment, Evotec said that its development of.